Skip to content

Hutchmed (China)

US · HCM #2639 by market cap Listed 2016
13.22 -0.23 -1.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Price chart

After-hours 13.22 0.00%
15.389.9913.222026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on HCM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -0.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation F

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 165.3x Better than 2%
Forward P/E 39.6x Better than 11%
Price / Sales 4.7x Better than 24%
P/E vs own 5-yr range 100th pctl Better than 2%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 8.8% Better than 61%
Net income CAGR (3Y) 25.5% Better than 77%
Profitability B+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 38.7% Better than 46%
Operating margin -6.5% Better than 16%
Net margin 83.3% Better than 99%
Return on equity 45.7% Better than 93%
Return on invested capital 38.1% Better than 98%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 4.7% Better than 83%
6-month return 10.3% Better than 72%
12-month return (ex latest month) 2.6% Better than 37%
Distance below 52-week high 19.0% Better than 62%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.0x Better than 86%
Debt to assets 5.6% Better than 78%
Interest coverage 175.1x Better than 95%
Free cash flow / net income 185.2% Better than 74%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.28%
1M -10.31%
3M +5.25%
6M +11.00%
YTD -0.83%
1Y -6.77%
3Y -28.69%
5Y -56.97%

Key statistics

Price & volume

Prev close
13.45
Open
13.45
Day range
13.13 - 13.45
Avg price
13.24
Volume
32.80K
Turnover
434.32K
Amplitude
2.38%
52-week range
9.77 - 16.33

Valuation

P/E
5.08
P/E (TTM)
165.25
P/B
1.83
EPS
2.60
Net profit
453.61M
Net assets
1.26B

Share structure

Market cap
2.31B
Float cap
1.39B
Shares out
174.47M
Float shares
105.22M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-03-17
52-week range 53% of range
9.77 16.33

19.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+323.24K net over the window

Short interest

Shares short
275.36K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Hutchmed (China) (HCM)?

Hutchmed (China) last traded at 13.22. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Hutchmed (China)'s market cap?

About 2.31B.

What is the P/E ratio of Hutchmed (China)?

The trailing twelve-month P/E is 165.25, above its own 5-year average of 0.09 — toward the top of its historical range (99.68% percentile). See the Valuation tab for the full history.

Does Hutchmed (China) pay a dividend?

Hutchmed (China) does not currently pay a regular dividend.

Is Hutchmed (China) a buy according to analysts?

The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 18.25, which implies 38.0% upside from the current price. This is not investment advice.

What is Hutchmed (China)'s StockVane Quant Rating?

The StockVane Momentum strategy currently rates Hutchmed (China) a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Hutchmed (China) discussion 0 comments

Add a comment